Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
about
The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D)Role of antispasmodics in the treatment of irritable bowel syndrome.Recent advances in pharmacological treatment of irritable bowel syndrome.Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome.Is Otilonium Bromide Really Effective for Treating Asian Patients With Irritable Bowel Syndrome?: Author's Reply.Efficacy of ramosetron in male patients with irritable bowel syndrome with diarrhea (neurogastroenterol motil 2011;23:1098-1104).Pharmacologic Agents for Chronic Diarrhea.Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trialsAre solifenacin and ramosetron really ideal to treat irritable bowel syndrome?Drug development for the irritable bowel syndrome: current challenges and future perspectivesLong-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome.Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice.New treatments for IBS.Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome.Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome.The safety of novel drugs used to treat irritable bowel syndrome.Treatment of abdominal pain in irritable bowel syndrome.New and Investigational Agents for Irritable Bowel Syndrome.Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study.New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.Treatment of IBS-D with 5-HT3 receptor antagonists vs spasmolytic agents: similar therapeutical effects from heterogeneous pharmacological targets.Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition.Acupuncture for Diarrhoea-Predominant Irritable Bowel Syndrome: A Network Meta-Analysis.Sex-Gender Differences in Irritable Bowel SyndromeContinuous administration of ramosetron with patient-controlled analgesia after laparoscopic distal gastrectomy does not delay postoperative bowel function recovery: A prospective, randomized, double-blinded study
P2860
Q27024521-A2EF5F37-0242-40A2-951E-88FDAC146AA3Q33661077-244F585E-354B-4CF8-8806-02E524236C41Q33958853-AD6A1C88-7737-47D7-BE97-B19DF27FF0EFQ34323319-ECA82C93-F3D3-4B6A-A173-97734FB76AADQ35730440-2BB9CDD9-CBC4-4EC8-A685-7729E277841AQ35885931-8539F15F-9C04-439E-AAFA-8DE9C5B5DFA6Q36271715-ADBBC2D1-7576-451B-AEF3-8D78B361451CQ36307366-329D02D3-B905-4AFE-8EF3-9EDF5862EB89Q36341742-976763FC-7269-4B01-8019-BFB27AC94C7CQ36579818-97A163A6-0789-4841-89B5-EEC20913E7B6Q37057059-D1879426-452D-445F-A834-20F224518CC8Q37200907-254B0FB8-6E5D-429B-BB12-79D0302D7D24Q37632259-F83F27CD-84ED-4838-A5FF-E45A7690B7E6Q38059436-5B1E75D8-23CE-4706-B028-6513C9422EC2Q38102063-302C7FFB-3A3F-4EDB-BC11-8770E1A679E4Q38178543-6A46A9AD-B6F5-4F52-874C-C281A733AFEFQ38199522-289EEC8A-54A9-4D3E-8B71-41375FF73CD6Q38213185-CC2CC8A6-AA82-448A-BACA-FD4DC49A95F1Q38601834-B7641AB9-D24A-43DD-9A33-9AF18DFF8CF2Q38630721-4F341EF2-404D-441C-9B9F-553F9EAFB300Q40072180-A44D4BE1-B3F2-4D3C-A926-E12B7B21B007Q42695148-0CD710EF-9D04-4D08-954A-9C160A665F87Q43336624-BF331BD2-AE57-4320-A926-5EF3483AEA47Q47196408-EB436B6D-A301-4D07-909F-5C16DA13D2DDQ55312184-4FB2F399-4601-4664-82C4-9A4919337156Q55448021-7A9AD4CB-D3B1-46C2-8695-C133820EF68BQ57819657-6A4C4AFC-EF5E-46B7-A72B-60E3CFF141BFQ58802063-893F9163-2DE5-41BA-B3AF-158477B1A724
P2860
Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Efficacy of ramosetron in the ...... ial, compared with mebeverine.
@en
Efficacy of ramosetron in the ...... ial, compared with mebeverine.
@nl
type
label
Efficacy of ramosetron in the ...... ial, compared with mebeverine.
@en
Efficacy of ramosetron in the ...... ial, compared with mebeverine.
@nl
prefLabel
Efficacy of ramosetron in the ...... ial, compared with mebeverine.
@en
Efficacy of ramosetron in the ...... ial, compared with mebeverine.
@nl
P2093
P2860
P50
P921
P1476
Efficacy of ramosetron in the ...... rial, compared with mebeverine
@en
P2093
P2860
P304
P356
10.1111/J.1365-2982.2011.01771.X
P577
2011-09-15T00:00:00Z